Answers are grounded in this paper and cite their sources.
This review discusses new drug trials targeting eosinophils and neutrophils in bullous pemphigoid, highlighting recent challenges.
Bullous pemphigoid (BP) is the most prevalent autoimmune blistering disorder. It is associated with high mortality partially due to side-effects of immunosuppressive drugs. Development of new therapeutics for BP has turned out to be exceedingly challenging, among others, due to frailty of the patients and heterogeneity of the disease. This review summarizes current clinical trials examining new potential drugs for BP. Strategies targeting the activity of eosinophils, complement activation, leukotriene B4, the neonatal Fc receptor, and TH2 cell cytokines are discussed. Strategies recently under investigation for BP have largely failed. Only the inhibition of IL-4/IL-13 signaling by dupilumab met its primary endpoint. However, its effects were rather modest, and limited to a patient subgroup. All strategies directly or indirectly targeting eosinophils, including the depletion of eosinophils by benralizumab, failed. The reason might be a more significant or redundant role of neutrophils in BP. Strategies targeting neutrophils, e.g. by inhibition of LTB4 should therefore be further pursued. Additionally, new kinase inhibitors, such as inhibitors of JAK, Syk, Src kinases, and BTK, should be tested because they would presumably inhibit multiple immune cell populations, including neutrophils, which is possibly required to achieve pronounced therapeutic effects in BP.
No takes yet. Share an insight, caveat, or question.
Olbrich et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: